### TABLE OF CONTENTS

#### HIGHLIGHTS

- **1611** Selected Articles from This Issue

#### CANCER GENES AND NETWORKS

- **1613** Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
  Arnout Schepers, Fleur Jochems, Cor Lieftink, Liqin Wang, Ziva Pogacar, Rodrigo Leite de Oliveira, Giulia De Conti, Roderick L. Beijersbergen, and Rene Bernards

- **1622** Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors
  Guoqing Qian, Jianping Guo, Karin A. Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh S. Ramalingam, Taofeek K. Owonikoko, Wenyi Wei, and Shi-Yong Sun

- **1635** MicroRNA-324-5p–CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness
  Dishari Ghatak, Arindam Datta, Tanaya Roychowdhury, Samit Chattopadhyay, and Susanta Roychoudhury

- **1651** Nestin Is Required for Spindle Assembly and Cell-Cycle Progression in Glioblastoma Cells
  Qinglin Wang, Hao Wu, Jian Hu, Haijuan Fu, Yanghui Qu, Yijun Yang, Kathy Q. Cai, Andrey Efimov, Minghua Wu, Tim Yen, Yuan Wang, and Zeng-Jie Yang

- **1666** REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer
  Weijing Liu, An Xie, Chunhua Tu, and Weipeng Liu

#### CANCER “-OMICS”

- **1676** Establishment of a Plasticity-Associated Risk Model Based on a SOX2- and SOX9-Related Gene Set in Head and Neck Squamous Cell Carcinoma
  Karam Khorani, Julia Schwaerzler, Sebastian Burkart, Ina Kurth, Dana Holzinger, Christa Flechtenmacher, Peter K. Plinkert, Karim Zaoui, and Jochen Hess

- **1688** PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells
  Shrikanth S. Gadad, Cristel V. Camacho, Venkat Malladi, Charles R. Hutti, Anusha Nagari, and W. Lee Kraus

#### CELL FATE DECISIONS

- **1699** HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

- **1712** IQGAP3, a YAP Target, Is Required for Proper Cell-Cycle Progression and Genome Stability
  Marina Leone, Salvador Cazorla-Vázquez, Fulvia Ferrazzi, Janica L. Wiederstein, Marco Gründl, Grit Weinstock, Silvia VergaraJauregui, Markus Eckstein, Marcus Krüger, Stefan Gaubatz, and Felix B. Engel

#### METABOLISM

- **1727** In Situ Analysis of N-Linked Glycans as Potential Biomarkers of Clinical Course in Human Prostate Cancer
  Lindsey R. Conroy, Alexandra E. Stanback, Lyndsay E.A. Young, Harrison A. Clarke, Grant L. Austin, Jinze Liu, Derek B. Allison, and Ramon C. Sun

#### NEW HORIZONS IN CANCER BIOLOGY

- **1739** Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
  Brian S. Canter, Calvin N. Leung, J. Christopher Fritton, Tom Bäck, Didier Rajon, Edouard I. Azzam, and Roger W. Howell
RNA BIOLOGY

1751 Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53-Mdm2 Axis
Shakur Mohibi, Jin Zhang, Mingyi Chen, and Xinbin Chen

TUMOR MICROENVIRONMENT AND IMMUNOBIOLOGY

1763 Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Alison B. Shupp, Manish Neupane, Lebaron C. Agostini, Gang Ning, Jonathan R. Brody, and Karen M. Bussard

ABOUT THE COVER

Amplification of HER2 and/or expression of pathogenic HER2 isoforms is a recognized oncogenic event in the natural history of certain breast cancers. While HER2-amplified breast cancers are treated uniformly, the specific roles of each HER2 alteration in a heterogeneous tumor have not been well defined. In their study on page 1699, and as depicted on the cover, Ginzel and colleagues employ a “cancer rainbow” mouse model in which multiple HER2 isoforms were barcoded with distinct fluorescent labels to trace tumor subpopulations expressing different HER2 isoforms (cyan, wild type; yellow, exon 16 splice isoform; magenta, NH2-terminally truncated isoform). The data demonstrate that the various HER2 alterations are associated with differential effects on epithelial specification, rate of tumor growth, and invasiveness. The authors conclude that programs underlying intratumor heterogeneity are established early in the tumorigenic process and can have major implications for disease trajectory.

doi: 10.1158/1541-7786.MCR-19-10-CVR